Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$150.30 USD

150.30
646,009

+0.34 (0.23%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics

Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.

Reasons to Hold Patterson Companies (PDCO) in Your Portfolio

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Here's Why You Should Hold McKesson (MCK) in Your Portfolio

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

Walgreens (WBA) to Report Q2 Earnings: What's in the Cards?

Walgreens (WBA) fiscal second-quarter performance is likely to benefit from strong growth in the United States and the International front

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

GE HealthCare (GEHC) Renews HealthCare Alliance With Hartford

GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.

DaVita HealthCare (DVA) Is Up 1.09% in One Week: What You Should Know

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

DaVita HealthCare (DVA) Is Up 1.09% in One Week: What You Should Know

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

UnitedHealth (UNH) Faces Investigation Following Cyberattack

A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.

Reasons to Add Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.

Revvity's (RVTY) New Launch to Boost Research Productivity

Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

Investors target stocks that have been on a bullish run lately. Stocks like HST, EAT, DVA and PPC that are seeing price strength have a high chance of carrying the momentum forward.

Here's Why You Should Retain National Vision (EYE) Stock Now

The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Merit Medical (MMSI) Launches FDA-Cleared Micro-Access System

Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

Accuray's (ARAY) solid product demand raises optimism about the stock.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

Johnson & Johnson (JNJ), Nvidia Unite to Boost AI for Surgery

Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.

Here's Why You Should Retain HealthEquity (HQY) Stock Now

HealthEquity's (HQY) strength in HSAs raises optimism about the stock.

Cencora (COR) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).